Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity

Journal of the National Cancer Institute

Volumn 100, Issue 13, 2008, Pages 950-961

  Snook, Adam E ^a   Stafford, Benjamin J ^a   Li, Peng ^a   Tan, Gene ^a   Huang, Lan ^a   Birbe, Ruth ^b   Schulz, Stephanie ^a   Schnell, Matthias J ^a   Thakur, Mathew ^a   Rothstein, Jay L ^c   Eisenlohr, Laurence C ^a   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NATRIURETIC PEPTIDE RECEPTOR C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNIZATION; IMMUNOGENICITY; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROPHYLAXIS;

ADENOVIRIDAE; ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; GUANYLATE CYCLASE; IMMUNOTHERAPY; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; RECEPTORS, PEPTIDE; RECOMBINANT PROTEINS; RESEARCH DESIGN;

EID: 46849089908     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn178     Document Type: Article

References (46)

1. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol. 2003;46(1):33-57.
2. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004;305(5681):200-205.
3. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22-32.
4. Alves PM, Levy N, Bouzourene H, et al. Molecular and immunological evaluation of the expression of cancer/testis gene products in human colorectal cancer. Cancer Immunol Immunother. 2007;56(6):839-847.
5. Snook A, Stafford B, Eisenlohr L, Rothstein J, Waldman S. Mucosally-restricted antigens as novel immunological targets for anti-tumor therapy. Biomarkers Med. 2007;1(1):187-202.
6. Belyakov IM, Derby MA, Ahlers JD, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci USA. 1998;95(4):1709-1714.
7. + cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest. 1998;102(12):2072-2081.
8. Eo SK, Gierynska M, Kamar AA, Rouse BT. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J Immunol. 2001;166(9):5473-5479.
9. Stevceva L, Abimiku AG, Franchini G. Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. Genes Immun. 2000;1(5):308-315.
10. Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell. 1990;63(5):941-948.
11. Carrithers SL, Barber MT, Biswas S, et al. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci USA. 1996;93(25):14827-14832.
12. Wolfe HR, Mendizabal M, Lleong E, et al. In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C-specific ligand. J Nucl Med. 2002;43(3):392-399.
13. Frick GS, Pitari GM, Weinberg DS, Hyslop T, Schulz S, Waldman SA. Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn. 2005;5(5):701-713.
14. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52(3):375-414.
15. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol. 2005;36(2):170-179.
16. Schulz S, Hyslop T, Haaf J, et al. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res. 2006;12(15):4545-4552.
17. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10-30.
18. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673-4680.
19. Schulz S, Lopez MJ, Kuhn M, Garbers DL. Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice. J Clin Invest. 1997;100(6):1590-1595.
20. Li P, Schulz S, Bombonati A, et al. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 2007;133(2):599-607.
21. McGettigan JP, Pomerantz RJ, Siler CA, et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol. 2003;77(1):237-244.
22. Plesa G, McKenna PM, Schnell MJ, Eisenlohr LC. Immunogenicity of cytopathic and noncytopathic viral vectors. J Virol. 2006;80(13):6259- 6266.
23. Zook MB, Howard MT, Sinnathamby G, Atkins JF, Eisenlohr LC. Epitopes derived by incidental translational frameshifting give rise to a protective CTL response. J Immunol. 2006;176(11):6928-6934.
24. Golovina TN, Morrison SE, Eisenlohr LC. The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J Immunol. 2005;174(5):2763-2769.
25. Carrithers SL, Parkinson SJ, Goldstein SD, Park PK, Urbanski RW, Waldman SA. Escherichia coli heat-stable enterotoxin receptors. A novel marker for colorectal tumors. Dis Colon Rectum. 1996;39(2):171-181.
26. Wai PY, Mi Z, Guo H, et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis. 2005;26(4):741-751.
27. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984;225(4669):1487-1489.
28. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a selfantigen and antitumor activity. Cancer Res. 2002;62(20):5770-5777.
29. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res. 2003;9(5):1837-1849.
30. Ando K, Guidotti LG, Cerny A, Ishikawa T, Chisari FV. CTL access to tissue antigen is restricted in vivo. J Immunol. 1994;153(2):482-488.
31. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med. 1998;188(2):409-414.
32. Allen S, Read S, DiPaolo R, et al. Promiscuous thymic expression of an autoantigen gene does not result in negative selection of pathogenic T cells. J Immunol. 2005;175(9):5759-5764.
33. + T-cell repertoire. Cancer Res. 2005;65(14):6443-6449.
34. Mozdzanowska K, Maiese K, Gerhard W. Th cell-deficient mice control influenza virus infection more effectively than Th- and B cell-deficient mice: evidence for a Th-independent contribution by B cells to virus clearance. J Immunol. 2000;164(5):2635-2643.
35. Qiu F, Cui Z. CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope. J Immunother (1997). 2007;30(2):180-189.
36. Anderson MS, Venanzi ES, Klein L, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395-1401.
37. Liston A, Lesage S, Wilson J, Peltonen L, Goodnow CC. Aire regulates negative selection of organ-specific T cells. Nat Immunol. 2003;4(4):350-354.
38. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307(5707):254-258.
39. Rescigno M, Urbano M, Valzasina B, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol. 2001;2(4):361-367.
40. Mayer L. Mucosal immunity and gastrointestinal antigen processing. J Pediatr Gastroenterol Nutr. 2000;30(suppl):S4-S12.
41. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002;16(1):1-4.
42. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004;21(4):527-538.
43. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of guthoming T cells by Peyer's patch dendritic cells. Nature. 2003;424:88-93.
44. + T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med. 2002;195(1):135-141.
45. Debruyne PR, Witek M, Gong L, et al. Bile acids induce ectopic expression of intestinal guanylyl cyclase C through nuclear factor-kappaB and Cdx2 in human esophageal cells. Gastroenterology. 2006;130(4):1191-1206.
46. Tan GS, McKenna PM, Koser ML, et al. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology. 2005;331(1):82-93.